Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Solid Tumor Clinical Trial

Official title: A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19

Status Terminated

Clinical Trial Summary

This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of participants infected with COVID-19. This is the first in-human study of this investigational product specifically in patients with severe COVID-19. Currently there are no FDA approved medications that improve the chance of survival in patients diagnosed with COVID-19. However there are usual treatments currently being used to help treat COVID-19 patients and BMS-986253 will be compared to these standard of care treatments in this study.

Clinical Trial Description

This is a single center, randomized, open-label, phase 2 trial to evaluate the time-to-improvement in the 7 point ordinal scale following treatment with anti-IL-8 therapy (BMS-986253) compared to standard of care in hospitalized patients with COVID-19 respiratory disease. Patients will be randomized 2:1 to receive either BMS-986253 or standard of care. Patients randomized to treatment with BMS-986253 will receive between 1-3 doses of therapy depending on their clinical status. Participants will be assessed daily while in the hospital and with then be followed for up to 1 year after discharge. ;

Related Conditions & MeSH terms

• COVID-19
• Hematologic Neoplasms
• Hematological Malignancy
• Sars-CoV2
• Solid Tumor

• NCT number: NCT04347226
• Study type: Interventional
• Source: Columbia University
• Status: Terminated
• Phase: Phase 2
• Start date: April 16, 2020
• Completion date: March 1, 2021